Trial Profile
Caelyx [doxorubicin liposomal] biweekly in heavily pretreated patients with relapsed ovarian cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2019
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 28 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2005 New trial record.